Comparative Clinical Pharmacokinetics a1 nd Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

(2020) Chloe Orkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

(2020) Susan Swindells et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)

(2019) Catriona Waitt et al.   PLOS MEDICINE

2490. Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV and End-Stage Renal Disease on Chronic Hemodialysis

(2019) Joseph J Eron et al.   Open Forum Infectious Diseases

Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV

(2018) Nikki Mulligan et al.   AIDS

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide

(2018) Paul E. Sax et al.   AIDS

Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps

(2018) Ruben van der Galiën et al.   CLINICAL PHARMACOKINETICS

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

(2018) Josep M Llibre et al.   LANCET

Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV

(2018) Jeremiah D. Momper et al.   AIDS

HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015

(2018) Robin M. Nance et al.   ANNALS OF INTERNAL MEDICINE

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial

(2018) Joseph J Eron et al.   Lancet HIV

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

(2017) Joel E. Gallant et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial

(2017) Paul E Sax et al.   Lancet HIV

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

(2017) Pedro Cahn et al.   Lancet HIV

Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors

(2016) Anthony T. Podany et al.   CLINICAL PHARMACOKINETICS

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment

(2016) Anton Pozniak et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

(2015) Jianping Zhang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Raltegravir in HIV-1–Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy

(2015) Maren I. Blonk et al.   CLINICAL INFECTIOUS DISEASES

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

(2015) David A Margolis et al.   LANCET INFECTIOUS DISEASES

Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans

(2015) Gary David Bowers et al.   XENOBIOTICA

Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients

(2015) Leonardo Calza et al.   Infectious Diseases

Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic Impairment

(2014) J. M. Custodio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Editorial Commentary: Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs

(2014) C. V. Fletcher   CLINICAL INFECTIOUS DISEASES

Pharmacokinetic Study of Raltegravir in HIV-Infected Patients With End-Stage Liver Disease: The LIVERAL-ANRS 148 Study

(2014) Caroline Barau et al.   CLINICAL INFECTIOUS DISEASES

Protecting the Fetus Against HIV Infection: A Systematic Review of Placental Transfer of Antiretrovirals

(2014) Shelley A. McCormack et al.   CLINICAL PHARMACOKINETICS

Raltegravir Pharmacokinetics During Pregnancy

(2014) D. Heather Watts et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Bioequivalence of a Dolutegravir, Abacavir, and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food

(2014) Stephen Weller et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: A randomized, three-way crossover study

(2014) Mari Shiomi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

(2014) A. Castagna et al.   JOURNAL OF INFECTIOUS DISEASES

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

(2013) Stephen Castellino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacological considerations on the use of antiretrovirals in pregnancy

(2013) Angela Colbers et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment

(2013) Stephen Weller et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

(2013) W. Spreen et al.   HIV CLINICAL TRIALS

Raltegravir pharmacokinetics in HIV/HCV-coinfected patients with advanced liver cirrhosis (Child-Pugh C)

(2013) B. Hernandez-Novoa et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

(2013) François Raffi et al.   LANCET INFECTIOUS DISEASES

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Etravirine on the Pharmacokinetics of the Integrase Inhibitor S/GSK1265744

(2012) Susan L. Ford et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals

(2012) Mona Arab-Alameddine et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

(2012) Matthew L. Rizk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

Intrapatient and Interpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting

(2012) Marco Siccardi et al.   THERAPEUTIC DRUG MONITORING

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

(2011) Sherene Min et al.   AIDS

Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir

(2011) Ivy Song et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

(2011) Ivy Song et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers

(2011) P. Patel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

(2011) Joseph J Eron et al.   LANCET INFECTIOUS DISEASES

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES

Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus-Seronegative Volunteers

(2010) J. J. Kiser et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug Interactions Should Be Evaluated in Patients

(2010) C V Fletcher   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of HIV

(2010) Polina German et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics

(2010) Diana M. Brainard et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial

(2010) Andrew R. Zolopa et al.   JOURNAL OF INFECTIOUS DISEASES

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

(2009) M. Iwamoto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

(2009) S. Min et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms

(2009) LA Wenning et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

Regulation of UDP-glucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination

(2007) H. Jeong et al.   XENOBIOTICA